The biopharmaceutical company said both figures were adjusted to reflect the sale of its ophthalmic product Omidria and related assets and liabilities to Rayner Surgical in December.
Analysts polled by Capital IQ expected a normalized loss of $0.06 per share, if comparable.
Net sales were $32.9 million, excluding the impact of the Omidria sale.
Analysts surveyed by Capital IQ expected revenue of $30.8 million, if comparable.
Omeros said it had $157.3 million of cash available for operations as of Dec. 31, along with $38.2 million in accounts receivable, which is expected to be collected in the current quarter.
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|